about
What's in a virus? Folk understandings of hepatitis C infection and infectiousness among injecting drug users in Kings Cross, SydneyInitiation to heroin injecting among heroin users in Sydney, Australia: cross sectional surveyA review of HIV prevention among young injecting drug users: A guide for researchersPerceptions of substance use, treatment options and training needs among Iranian primary care physiciansPatterns of drug use among a sample of drug users and injecting drug users attending a General Practice in IranWomen-only drug treatment services and needs in Iran: the first review of current literature.HIV Responses in Arab States on the Southern Persian Gulf Border: The First ReviewThe perfect storm: incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central AsiaPer-event probability of hepatitis C infection during sharing of injecting equipmentHIV, prisoners, and human rights.Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners.Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees.Shooting gallery operation in the context of establishing a medically supervised injecting center: Sydney, Australia.Incidence of primary hepatitis C infection and risk factors for transmission in an Australian prisoner cohortSurvey of drug consumption rooms: service delivery and perceived public health and amenity impact.Prison-based syringe exchange programmes: a review of international research and development.Examining HIV, drug use and risk behaviours: A case study in the custodial settings of Thailand and Indonesia.Methamphetamine use and treatment in Iran: A systematic review from the most populated Persian Gulf country.Substance Use and HIV Among Female Sex Workers and Female Prisoners: Risk Environments and Implications for Prevention, Treatment, and Policies.Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia.HIV in prison in low-income and middle-income countries.A literature review of international implementation of opioid substitution treatment in prisons: equivalence of care?Drug and alcohol use and treatment for Australian Indigenous and non-Indigenous prisoners: demand reduction strategies.Monitoring a Prison Opioid Treatment Program Over a Period of Change to Clinical Governance Arrangements, 2007-2013.The development and evaluation of stimulant treatment programmes.Drug use treatment and harm reduction programs in Iran: A unique model of health in the most populated Persian Gulf country.HIV and Hepatitis C Virus Infection and Risk Behaviors Among Heterosexual, Bisexual, and Lesbian Women Who Inject Drugs in Australia.A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia.Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.Detection of drugs in Australian prisons: supply reduction strategies.People who inject drugs in prison: HIV prevalence, transmission and prevention.A prospective study of hepatitis C incidence in Australian prisoners.Injecting drug users' understanding of hepatitis C.Incidence and risk for acute hepatitis C infection during imprisonment in Australia.Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort.Presence of hepatitis C virus in syringes confiscated in prisons in Australia.Decreased heroin availability in Sydney in early 2001.Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration.Increased access to opioid substitution treatment in prisons is needed to ensure equivalence of care.
P50
Q24795489-35351DF3-5C7C-487B-B63B-8293A6597003Q24795730-D95E1A6D-911D-4398-8DA1-59E0EF952818Q24805259-13BA9ECA-9317-4CD8-9900-6C1804BA0254Q24814338-3E665270-11B7-4B85-8C6D-C98749F137E3Q25256595-C8491311-730C-4A94-A971-F9D687809754Q27687175-EE396E72-3D4C-42BE-9E55-B3EDA714CA1EQ28077684-8A28FDFC-BC5D-407B-A851-7E73C84CC290Q28077903-DCCA4A02-B280-4EEF-8ECD-25A17FA47A3FQ28540414-9A09B2D5-88EF-4A06-89D3-88F6771379ACQ30248940-509D7CB4-50AA-4FA4-A4FD-8C1123422D9CQ30248941-D473FF85-1084-4851-83B6-A17B3A97BABCQ30248942-2A391023-FF0C-4BEF-973B-D8F5A582F29CQ33271708-5D79AA77-9B24-41E9-8CE3-FB5462ECB93CQ33724826-3859C524-FCDB-4A4D-B9B5-E3FC934BA957Q34454980-1D7E65FE-6216-463E-B4FA-2E5337C8E0E0Q35048065-437C641E-ABED-4152-A70D-83538ACEE81FQ35574685-BFC93DEB-4181-44A0-B873-7199BB13B9B6Q35677943-93743715-A3F3-4A4F-8F5C-BACF48AB6FB9Q35825560-E201F458-3D16-471A-8A63-F24E1F201AB9Q36079786-DAA3DBED-17B7-4C80-81B0-D7C3CA284910Q36272388-AA37C375-7018-410B-A142-574028802228Q36689479-3A64C165-766F-45FC-B5A2-834597C26773Q37381542-E1940250-A6AC-47E1-B71D-64A6E19FFCBBQ38370548-89A35AB4-49E1-4C4E-8EEF-CB2DF7DAF750Q38405428-DE70C146-A0E9-49CB-AFFA-EDC1B8D14338Q38498525-22393B9F-AA98-4CE7-AD07-5213ADFE4B9DQ38546125-FB0D3A1A-156E-4635-9EAF-DDE3CCF044EEQ38918364-2BA99912-1998-4572-8137-6D6AA37F76FCQ39668570-AF6F3850-9D1E-4EBE-8AFA-01F7A29F4430Q40556040-E82D6281-C6AE-4120-8F1D-7D2B4CB477A6Q41237961-1779637A-FAB7-41CC-88E9-65BF8878358AQ41458000-1C9A9545-5A3A-46CF-B13B-AA4D2F1BA968Q42213249-49DA07CE-FA2B-4787-AB3D-5FCBF4BB2B4EQ42596155-E2BF221B-D4A7-4FCB-AD80-3ED361697AACQ42646124-1519CB50-A24F-44D0-B53A-699A575FBD59Q42984783-DEF26975-BC32-4BBB-9356-3EB8EEB652FDQ42991378-8E4E6AF1-E367-49C6-B439-73ED99463665Q44256503-98D42D42-3AA8-4F56-A737-7C6E47F78CA5Q44330216-1979800F-6CBA-4B96-BD0E-31E5D3223D20Q44337929-85E2C08B-654F-424E-AF0C-D89094639B3E
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Kate Dolan
@ast
Kate Dolan
@en
Kate Dolan
@es
Kate Dolan
@nl
Kate Dolan
@sl
type
label
Kate Dolan
@ast
Kate Dolan
@en
Kate Dolan
@es
Kate Dolan
@nl
Kate Dolan
@sl
prefLabel
Kate Dolan
@ast
Kate Dolan
@en
Kate Dolan
@es
Kate Dolan
@nl
Kate Dolan
@sl
P1053
G-7859-2017
P106
P1153
7102282862
P21
P31
P3829
P496
0000-0002-9848-807X